# CUE catalysts: Cue Biopharma, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/cue/catalysts

> Cue Biopharma, Inc. (CUE) has no upcoming catalysts in this calendar. The latest recorded is the CUE-221 topline data readout, September 20, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for CUE?

Cue Biopharma, Inc. (CUE) has no upcoming catalysts in this calendar. The latest recorded is the CUE-221 topline data readout, September 20, 2026. SEC Form 8-K: "On September 20, 2026, the Company announced positive topline data from a Phase 2 clinical trial of CUE-221 in CSU conducted in China by Genesis Life Sciences, an affiliate of Ascendant Health Ltd. This Phase 2 clinical trial enrolled 145 participants with moderate to severe CSU whose disease remained inadequately controlled despite treatment with H1-antihistamines." [Calendar and source filings](https://sec-api.dev/companies/cue/catalysts)

Source: SEC Form 8-K, accession 0001193125-26-396094, https://www.sec.gov/Archives/edgar/data/1645460/000119312526396094/d21238d8k.htm (retrieved 2026-11-12). Last confirmed 2026-09-21. Cite: https://sec-api.dev/companies/cue/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Cue Biopharma, Inc. |
| Ticker | CUE (Nasdaq) |
| SEC CIK | 1645460 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/cue |

## Cash runway

Cash $17.4M as of 2026-06-30; quarterly burn $29.0M; about 1.8 months of runway at that rate (XBRL company facts, accession 0001193125-26-352128).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 30, 2024 | [CUE-101 trial start](https://sec-api.dev/pdufa/cue-101) | CUE |  | completed | "As of September 30, 2024, two of these milestones had been achieved, as we had filed an investigational new drug application, or IND, in 2019, and initiated the investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in 2021." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1645460/000095017024127005/cue-20240930.htm)) |
| November 14, 2024 | [Cue Biopharma, Inc. earnings report](https://sec-api.dev/companies/cue/catalysts) | CUE |  | completed | "Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645460/000095017024127004/cue-ex99_1.htm)) |
| December 31, 2024 | [CUE-101 trial start](https://sec-api.dev/pdufa/cue-101) | CUE |  | completed | "As of December 31, 2024, two of these milestones had been achieved, as we had filed an investigational new drug application, or IND, in 2019, and initiated the investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in 2021." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1645460/000095017025047677/cue-20241231.htm)) |
| March 31, 2025 | [CUE-101 trial start](https://sec-api.dev/pdufa/cue-101) | CUE |  | completed | "As of March 31, 2025, two of these milestones had been achieved, as we had filed an IND application in 2019, and initiated the investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in 2021." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1645460/000095017025069125/cue-20250331.htm)) |
| March 31, 2025 | [Cue Biopharma, Inc. earnings report](https://sec-api.dev/companies/cue/catalysts) | CUE |  | completed | "Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645460/000095017025047678/cue-ex99_1.htm)) |
| May 12, 2025 | [Cue Biopharma, Inc. earnings report](https://sec-api.dev/companies/cue/catalysts) | CUE |  | completed | "Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645460/000095017025069124/cue-ex99_1.htm)) |
| June 30, 2025 | [CUE-101 trial start](https://sec-api.dev/pdufa/cue-101) | CUE |  | completed | "As of June 30, 2025, two of these milestones had been achieved, as we had filed an IND application in 2019, and initiated the investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in 2021." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1645460/000095017025107270/cue-20250630.htm)) |
| Aug 2025 | [CUE-102 trial start](https://sec-api.dev/pdufa/cue-102) | CUE |  | completed | "In addition, we are enabling an investigator sponsored Phase 1b, open-label study to evaluate CUE-102 in recurrent glioblastoma (rGBM) with the first patient dosed in August 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1645460/000119312525277466/cue-20250930.htm)) |
| August 12, 2025 | [Cue Biopharma, Inc. earnings report](https://sec-api.dev/companies/cue/catalysts) | CUE |  | completed | "Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645460/000095017025107268/cue-ex99_1.htm)) |
| September 30, 2025 | [CUE-101 trial start](https://sec-api.dev/pdufa/cue-101) | CUE |  | completed | "As of September 30, 2025, two of these milestones had been achieved, as we had filed an IND application in 2019, and initiated an investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in locally advanced HNSCC in 2021." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1645460/000119312525277466/cue-20250930.htm)) |
| November 12, 2025 | [Cue Biopharma, Inc. earnings report](https://sec-api.dev/companies/cue/catalysts) | CUE |  | completed | "Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645460/000119312525277468/cue-ex99_1.htm)) |
| December 31, 2025 | [CUE-101 trial start](https://sec-api.dev/pdufa/cue-101) | CUE |  | completed | "As of December 31, 2025, two of these milestones had been achieved, as we had filed an IND application in 2019, and initiated an investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in locally advanced HNSCC in 2021." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1645460/000119312526108287/cue-20251231.htm)) |
| March 16, 2026 | [Cue Biopharma, Inc. earnings report](https://sec-api.dev/companies/cue/catalysts) | CUE |  | completed | "Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645460/000119312526108292/cue-ex99_1.htm)) |
| March 31, 2026 | [CUE-101 trial start](https://sec-api.dev/pdufa/cue-101) | CUE |  | completed | "As of March 31, 2026, two of these milestones had been achieved, as we had filed an IND application in 2019, and initiated an investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in locally advanced HNSCC in 2021." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1645460/000119312526224091/cue-20260331.htm)) |
| June 30, 2026 | [CUE-101 trial start](https://sec-api.dev/pdufa/cue-101) | CUE |  | completed | "As of June 30, 2026, two of these milestones had been achieved, as we had filed an IND application in 2019, and initiated an investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in locally advanced head and neck squamous cell carcinoma in 2021." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1645460/000119312526352128/cue-20260630.htm)) |
| Q3 2026 | [Cue Biopharma, Inc. topline data readout](https://sec-api.dev/companies/cue/catalysts) | CUE |  | scheduled | "Phase 2 data readout in Chronic Spontaneous Urticaria anticipated by the end of the third quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645460/000119312526352126/cue-ex99_1.htm)) |
| 2H 2026 | [CUE-401 trial start](https://sec-api.dev/pdufa/cue-401) | CUE |  | scheduled | "Cue Biopharma plans to initiate global Phase 2b trial in food allergy following anticipated results in 2H 2026 from Ascendant Health-led Phase 2 study in chronic spontaneous urticaria" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645460/000119312526198588/d128047dex991.htm)) |
| August 14, 2026 | [Cue Biopharma, Inc. earnings report](https://sec-api.dev/companies/cue/catalysts) | CUE |  | completed | "Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645460/000119312526352126/cue-ex99_1.htm)) |
| September 20, 2026 | [CUE-221 topline data readout](https://sec-api.dev/pdufa/cue-221) | CUE |  | completed, positive | "On September 20, 2026, the Company announced positive topline data from a Phase 2 clinical trial of CUE-221 in CSU conducted in China by Genesis Life Sciences, an affiliate of Ascendant Health Ltd. This Phase 2 clinical trial enrolled 145 participants with moderate to severe CSU whose disease remained inadequately controlled despite treatment with H1-antihistamines." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1645460/000119312526396094/d21238d8k.htm)) |

## Drugs

- [CUE-101](https://sec-api.dev/pdufa/cue-101): 
- [CUE-102](https://sec-api.dev/pdufa/cue-102): 
- [CUE-221](https://sec-api.dev/pdufa/cue-221): 
- [CUE-401](https://sec-api.dev/pdufa/cue-401): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/cue/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CUE catalysts: Cue Biopharma, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/cue/catalysts

```bibtex
@misc{secapidev_companies_cue_catalysts_20261116,
  title        = {CUE catalysts: Cue Biopharma, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/cue/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_cue_catalysts_20261116","title":"CUE catalysts: Cue Biopharma, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/cue/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
